Pharma BD Deal Intelligence
Merck KGaA's $5.8B acquisition of Versum Materials extended its electronics materials business through outright ownership rather than partnership. The deal closed with Merck absorbing Versum's specialty chemicals portfolio for the semiconductor and display industries.
Merck KGaA acquired Versum Materials for $5.8B for electronics materials.
Versum Materials accepted Merck KGaA's sweetened acquisition offer of $53 per share after terminating its previously announced merger with Entegris, in a deal…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Merck KGaA acquired Versum Materials for $5.8B for electronics materials.
Merck KGaA/Versum Materials is a non-pharmaceutical transaction — Versum's portfolio is semiconductor process chemicals and deposition gases (electronic materials). No pharmaceutical competitive landscape applies. The relevant industrial competitor set is Air Liquide, Linde, SK Materials, and Entegris.
Versum accepted improved offer from Merck KGaA after initially pursuing Entegris merger.
SAMR (China) clearance obtained. Versum integrated into Semiconductor Solutions within Performance Materials.
Merck KGaA realized expected annual synergies of EUR75M by third full year post-close.
See timeline for full assessment. Assessment of Merck KGaA's $5.8B acquisition of Versum Materials and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck KGaA / Versum Materials (this deal) | 2019 | $5.8B | 80 |
| Merck KGaA / Millipore Corporation | 2010 | $7.2B | 88 |
| Merck KGaA / Sigma-Aldrich Corporation | 2014 | $17.0B | 80 |
| Merck KGaA / Serono SA | 2006 | $13.2B | 74 |
| Merck KGaA / SpringWorks Therapeutics | 2025 | $3.4B | 72 |
| Merck KGaA / Threshold Pharmaceuticals, Inc. | 2012 | $550M | — |
| Merck KGaA / Debiopharm | 2021 | $1.1B | — |
← Browse all deals · How we score deals
More: 2019 deals · Merck KGaA deals